ArticleRisk analysis : an official publication of the Society for Risk Analysis2026
Valuing Mortality Risk Reductions and Health Improvements: A Life Expectancy Framework to Harmonize Policy Traditions.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many public policies directly affect an individual's mortality risk. The value of longevity gains has traditionally been monetized through three different concepts: value per statistical life (VSL), value per statistical life year (VSLY), and willingness-to-pay for a quality-adjusted life year (WTP-QALY). By adopting gains in life expectancy as the unifying metric and combining it with preference-based information on health and longevity, we set out an approach that would generate three measures that are conceptually linked at the individual level. In particular, explicitly integrating preferences over health impacts would allow for the WTP-QALY to be estimated alongside the VSL and VSLY. We argue that our approach has advantages over the direct and modeling methods developed in the literature to date. In addition, we clarify how using the proposed framework could deliver values allowing for consistent decision-making across policy domains and government departments in ex ante regulatory assessment while simultaneously honoring the different empirical estimation practices across government departments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.